GlaxoSmithKline plc (NYSE:GSK) Shares Sold by BLB&B Advisors LLC
BLB&B Advisors LLC trimmed its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 39.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,322 shares of the pharmaceutical company’s stock after selling 11,958 shares during the quarter. BLB&B Advisors LLC’s holdings in GlaxoSmithKline were worth $654,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of GSK. Marshall Wace North America L.P. acquired a new position in shares of GlaxoSmithKline during the first quarter worth about $62,000. IHT Wealth Management LLC grew its position in GlaxoSmithKline by 32.4% during the third quarter. IHT Wealth Management LLC now owns 16,112 shares of the pharmaceutical company’s stock worth $606,000 after buying an additional 3,940 shares during the period. Jeppson Wealth Management LLC acquired a new position in GlaxoSmithKline during the third quarter worth about $54,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its position in GlaxoSmithKline by 66.4% during the third quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 12,962 shares of the pharmaceutical company’s stock worth $488,000 after buying an additional 5,172 shares during the period. Finally, Brinker Capital Investments LLC acquired a new position in GlaxoSmithKline during the third quarter worth about $1,107,000. Institutional investors and hedge funds own 11.83% of the company’s stock.
Shares of NYSE GSK opened at $37.70 on Wednesday. GlaxoSmithKline plc has a 12-month low of $33.26 and a 12-month high of $43.18. The company has a market capitalization of $101.51 billion, a PE ratio of 11.60, a price-to-earnings-growth ratio of 2.93 and a beta of 0.67. The company has a debt-to-equity ratio of 1.13, a current ratio of 0.90 and a quick ratio of 0.61. The firm’s 50-day moving average is $36.04 and its two-hundred day moving average is $36.54.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 8th. Investors of record on Friday, February 19th were paid a dividend of $0.628 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date was Thursday, February 18th. This represents a $2.51 annualized dividend and a dividend yield of 6.66%. GlaxoSmithKline’s dividend payout ratio is presently 79.50%.
GSK has been the topic of several recent analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, February 9th. SVB Leerink restated a “market perform” rating on shares of GlaxoSmithKline in a research report on Monday, March 29th. Morgan Stanley restated an “equal weight” rating on shares of GlaxoSmithKline in a research report on Tuesday. Zacks Investment Research raised shares of GlaxoSmithKline from a “strong sell” rating to a “hold” rating and set a $40.00 price target on the stock in a report on Tuesday. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, February 11th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average target price of $40.00.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.